BROOKS LABORATORIES

BSE: 533543 29 Jun 2025

Healthcare

₹ 136.5

BROOKS LABORATORIES LIMITED specializes in Pharmaceuticals within the Healthcare sector.

BROOKS LABORATORIES

BSE: 533543 29 Jun 2025

Healthcare

₹ 136.5

BROOKS LABORATORIES LIMITED specializes in Pharmaceuticals within the Healthcare sector.

Book Value

39.1

Dividend Yield

0.0%

Debt to Equity

0.07

Stock P/E

147.0

Market Cap

448.0 Cr

BROOKS LABORATORIES - Share Price & Details

Market Cap

₹448.0

High /Low

203.0 / 82.0

Stock P/E

147.0

Book Value

₹39.1

Dividend Yield

0.0

ROCE

4.31

ROE

₹3.3

Face Value

10.0

PEG Ratio

8.98

EVEBITDA

₹77.5

Debt

7.58

CMP / FCF

-144.0

Debt to equity

₹0.07

NP Ann

3.05

High price all time

203.0

Piotroski score

₹7.0

Graham Number

30.2

No. Eq. Shares

2.95

Net CF

₹-0.08

Net profit

3.05

Price to book value

3.89

Interest Coverage

₹4.14

Low price all time

10.3

Industry PE

32.7

Reserves

₹85.6

Free Cash Flow

₹0.67

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
LOOKS HEALTH SERVICES LIMITED	NA	NA	NA	NA	5.11	256.0
Triochem Products Ltd.,	NA	NA	NA	NA	0
BROOKS LABORATORIES LTD.	NA	NA	NA	NA	448.0	147.0
LYKA LABS LTD.	NA	NA	NA	NA	407	51.3
EVEREST ORGANICS LTD.	NA	NA	NA	NA	391

Peer Comparison Chart

About BROOKS LABORATORIES

BROOKS LABORATORIES LIMITED, with Security Code 533543, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Latest News

Brooks Laboratories Adjusts Evaluation Score Amid Mixed Financial Performance and Growing Investor Interest

(28 Jun 2025)

Brooks Laboratories has recently adjusted its evaluation score, reflecting a shift in technical trends. The company has delivered a strong...

Brooks Labs Standalone March 2025 Net Sales at Rs 23.32 crore, up 31.57% Y-o-Y

(12 Jun 2025)

Net Sales at Rs 23.32 crore in March 2025 up 31.57% from Rs. 17.72 crore in March 2024. Story continues below Advertisement.

How has been the historical performance of the Brooks Lab.?

(11 Jun 2025)

Brooks Lab. has shown fluctuating financial performance, with net sales increasing to Rs 82.56 crore in March 2025, but still reporting a negative profit...

Brooks Laboratories Faces Evaluation Shift Amidst Financial Health Concerns and Investor Confidence

(08 Jun 2025)

Brooks Laboratories, a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its evaluation, reflecting a shift in its technical...

Brooks Labs Consolidated March 2025 Net Sales at Rs 23.32 crore, up 31.57% Y-o-Y

(06 Jun 2025)

Net Sales at Rs 23.32 crore in March 2025 up 31.57% from Rs. 17.72 crore in March 2024. Story continues below Advertisement.

Brooks Laboratories Faces Increased Volatility Amid Declining Investor Participation

(06 Jun 2025)

Brooks Laboratories Ltd faced notable trading activity, hitting its lower circuit limit and closing at Rs 142.5, down from the previous...

Quarterly Table

Standalone Consolidated

Metrics	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	15.9	12.0	12.6	15.7	24.3	21.7	17.7	17.9	20.8	20.5
Expenses	16.2	13.5	12.7	15.7	22.6	20.7	17.3	17.7	19.3	18.9
Operating Profit	-0.3	-1.5	-0.1	0.0	1.7	1.1	0.4	0.3	1.5	1.6
OPM %	-1.69%	-12.27%	-0.94%	0.16%	7.06%	5.04%	2.14%	1.57%	7.26%	7.68%
Other Income	0.1	0.1	0.0	0.1	0.1	0.2	0.7	0.1	0.2	0.0
Interest	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.3
Depreciation	0.4	0.4	0.4	0.4	0.4	0.4	0.5	0.4	0.4	0.4
Profit before tax	-0.8	-2.1	-0.7	-0.5	1.2	0.6	0.3	-0.2	1.0	0.9
Tax %	0%	0%	0%	0%	0%	-4.3%	0%	0%	0%	0%
Net Profit	-0.8	-2.1	-0.7	-0.5	1.2	0.6	0.3	-0.2	1.0	0.9
EPS in Rs	-0.33	-1.68	-0.29	-0.22	0.46	0.23	0.1	-0.08	0.36	0.36

Metrics	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	18.1	15.3	12.6	15.7	24.3	21.7	17.7	17.9	20.8	20.5
Expenses	27.3	23.9	16.3	19.6	25.4	25.1	17.3	19.9	24.2	22.0
Operating Profit	-9.2	-8.6	-3.7	-3.9	-1.1	-3.4	0.4	-1.9	-3.4	-1.5
OPM %	-51.02%	-55.9%	-29.32%	-24.92%	-4.53%	-15.45%	2.14%	-10.71%	-16.4%	-7.28%
Other Income	0.1	0.4	0.0	0.1	0.1	0.2	0.7	0.1	0.2	0.0
Interest	0.6	0.7	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.3
Depreciation	2.3	2.3	0.4	0.4	0.4	0.4	0.5	0.4	0.4	0.4
Profit before tax	-12.0	-11.5	-4.3	-4.5	-1.6	-3.9	0.3	-2.4	-4.0	-2.1
Tax %	-32.1%	-15.2%	0%	0%	0%	-4.3%	0%	0%	0%	0%
Net Profit	-7.9	-9.5	-4.3	-4.5	-1.6	-3.9	-9.6	-2.4	-4.0	-2.1
EPS in Rs	-3.19	-2.03	-1.74	-1.75	-0.64	-1.51	-3.77	-0.94	-1.51	-0.82

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	-1%
5 Years:	8%
3 Years:	1%
TTM:	28%

Compounded Profit Growth
10 Years:	-14%
5 Years:	16%
3 Years:	28%
TTM:	240%

Stock Price CAGR
10 Years:	14%
5 Years:	38%
3 Years:	15%
1 Year:	49%

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	1%
TTM:	28%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	-44%

Stock Price CAGR
10 Years:	14%
5 Years:	38%
3 Years:	15%
1 Year:	49%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

BROOKS LABORATORIES

BROOKS LABORATORIES

BROOKS LABORATORIES - Share Price & Details

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About BROOKS LABORATORIES

Latest News

Brooks Laboratories Adjusts Evaluation Score Amid Mixed Financial Performance and Growing Investor Interest

Brooks Labs Standalone March 2025 Net Sales at Rs 23.32 crore, up 31.57% Y-o-Y

How has been the historical performance of the Brooks Lab.?

Brooks Laboratories Faces Evaluation Shift Amidst Financial Health Concerns and Investor Confidence

Brooks Labs Consolidated March 2025 Net Sales at Rs 23.32 crore, up 31.57% Y-o-Y

Brooks Laboratories Faces Increased Volatility Amid Declining Investor Participation

Brooks Laboratories Reports Strongest Sales and Profit Metrics Since Last Year

Brooks Laboratories reports consolidated net loss of Rs 1.46 crore in the March 2025 quarter

Brooks Laboratories Faces Mixed Technical Signals Amid Declining Profits and Increased Investor Interest

Brooks Laboratories Faces Financial Challenges Amid Rising Institutional Investor Interest

Brooks Laboratories Faces Evaluation Shift Amid Mixed Technical Signals and Fundamental Challenges

Brooks Laboratories to declare Quarterly Results

Mutual Funds increased stake in 14 pharma stocks in Q4FY25; do you own any?

Brooks Laboratories Shows Technical Improvement Amid Long-Term Financial Challenges

Brooks Laboratories - Unique Picks: These 7 stocks held by only one MF scheme surge 20-40% in over a month

Nifty 50 reclaims 22,900— 10 key highlights of Indian stock market today

20% Upper Circuit: GRS and 15 other stocks that hits upper circuit today

Ruby Mills Ltd leads gainers in 'B' group

Q3 Results Today: SJVN, Hindalco, United Breweries, Nazara Tech Among 460 Firms To Declare Earnings On Feb. 13

Brooks Laboratories Achieves All-Time High Stock Price of Rs. 200.05 Amid Mixed Performance

Brooks Laboratories Experiences Revision in Stock Score Amid Record Highs and Sector Underperformance

Brooks Laboratories Experiences Revision in Its Score Amid Strong Market Performance

Brooks Laboratories Hits 52-Week High of Rs. 188.6 with 38.73% Gains

Brooks Laboratories Hits 52-Week High of Rs. 196.15, Up 44.28% in 20 Days

Brooks Laboratories Limited Appoints Ms. Krutika Mohan Rane as Company Secretary & Compliance Officer, Effective 26 December 2024

Q2 results today: Asian Paints, Divis Labs, TVS Electronics, Aurobindo Pharma & Uttkarsh Small Finance Bank among others | Stock Market News

Don't Ignore The Insider Selling In Brooks Laboratories

Brooks Laboratories Reports Mixed Financial Results for Q2 2024, Operating Cash Flow Shows Growth

Brooks Labs Standalone September 2024 Net Sales at Rs 20.79 crore, down 14.49% Y-o-Y

Q2 results today: Asian Paints, TVS Electronics among many others to declare quarterly results on November 9; check list

Brooks Labs Consolidated September 2024 Net Sales at Rs 20.79 crore, down 14.49% Y-o-Y

Asian Paints, Doms Industries, Utkarsh Small Finance Bank Among 90+ Companies To Declare Q2 Results Today

Q2 Results Today: Asian Paints, Divis Labs, Utkarsh SFB among 92 companies to declare quarterly earnings on Saturday, Nov 9

Brooks Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024

Brooks Laboratories reports consolidated net loss of Rs 3.96 crore in the September 2024 quarter

Brooks Laboratories | Price Return FY25 so far: 57% - 9 unique stocks held by MF schemes jump over 50% in FY25

9 unique stocks held by MF schemes jump over 50% in FY25

Residue Testing Market: Global Size, Share, Growth, Forecast, Top Major Key Players 2024-2033

Brooks Laboratories to hold AGM

Brooks Labs Consolidated June 2024 Net Sales at Rs 17.93 crore, up 14.2% Y-o-Y

Brooks Labs Standalone June 2024 Net Sales at Rs 17.93 crore, up 14.2% Y-o-Y

Brooks Laboratories reports consolidated net loss of Rs 2.41 crore in the June 2024 quarter

Brooks Laboratories First Quarter 2025 Earnings: ₹0.94 loss per share (vs ₹1.81 loss in 1Q 2024)

Brooks Laboratories Reports Mixed Financial Results for Q2 2024, Shows Potential for Growth

What Quant Mutual Fund bought and sold in July? Here’s the breakup

What Quant Mutual Fund bought and sold in July? Here’s the breakup - Portfolio Shuffle

Moneycontrol Daily: Your Essential 7

100 out of 178 firms held by Quant MF trade lower following front-running allegations

What Quant Mutual Fund bought and sold in May? Here is the break up

Brooks Laboratories Full Year 2024 Earnings: ₹7.67 loss per share (vs ₹8.46 loss in FY 2023)

Brooks Laboratories Share Price

Coral Laboratories Share Price

Brooks Laboratories' Stock Reaches 52-Week High, Shows Strong Performance in Market

Brooks Laboratories Reports Strong Financial Growth

NPPA Announces Landmark 25%-30% Price Drop on Vital Medications, Bringing Relief to Indian Consumers

Dispatch from the lab of the future

Alkem Laboratories Ltd gains for fifth session

NPPA fixes price for various FDCs having Sitagliptin, Linagliptin

Q3 Results Announced Today: Maruti Suzuki, Adani Wilmar, Bank Of Baroda, Dabur, Ambuja Cements & More

Stocks To Watch: Vodafone, ITC, L&T, Muthoot Microfin, ZEEL, BPCL, Maruti Suzuki

NSE Bulk Deals, August 8: Piramal Pharma, Birla Cable, Debock Ind, other major deals took place on Tuesday

Brooks Laboratories Ltd fixes record date for 1:16 rights issue

2 Breakout Shares Looking ‘Superb’ on Charts!

Brooks Laboratories Ltd Share Price Today, BROOKS Share Price NSE, BSE

Brooks Lab's subsidiary receives USFDA approval for Meropenem Injection; Stock zooms 5%

Brooks Laboratories gets USFDA approval for Meropenem

Brooks Labs hits the roof after subsidiary gets US FDA nod for antibiotic injection

Brooks announces new investments to build an integrated carbapenem business

Brooks Labs announces additional investment of Rs 74.5 cr by JV partner SteriScience

Brooks Laboratories Ltd posts Rs. 3.36 crore PAT in Q2

Strides to invest Rs 135 crore to pick about 54% stake in SteriScience Pharma